Close Menu

    Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    What's Hot

    Ajman Government Media Office hosts Foreign Affairs Undersecretary at THE SIGNAL with a clear message: ‘The UAE does not seek the signal – it creates it’

    November 22, 2026

    Humaid bin Ammar attends day two of Ajman Media Forum 2026 and honours participants and partners

    November 22, 2026

    Ajman Government Media Office’s THE SIGNAL forum features Saeed Al Eter on how public trust and a successful development model underpin UAE soft power in times of crisis

    November 22, 2026
    Facebook X (Twitter) Instagram
    • Home
    • Contact Us
    Doha MirrorDoha Mirror
    • Automotive
    • Business
    • Entertainment
    • Health
    • Lifestyle
    • Luxury
    • News
    • Sports
    • Technology
    • Travel
    Doha MirrorDoha Mirror
    Home » MedAlliance Enrolls First US Patient into its Third FDA IDE Study: SFA SELUTION4SFA
    PR Newswire

    MedAlliance Enrolls First US Patient into its Third FDA IDE Study: SFA SELUTION4SFA

    May 5, 2023
    Share Facebook Twitter Pinterest LinkedIn Tumblr Reddit Telegram Email

    GENEVA, May 5, 2023 /PRNewswire/ — The first US patient has been enrolled in the SELUTION4SFA Sirolimus DEB study by Dr. Arthur Lee at the Cardiac & Vascular Institute in Florida. This study evaluates SELUTION SLR™ in the treatment of occlusive disease of the superficial femoral artery (SFA) and proximal popliteal artery (PPA) and has been designed to support FDA approval. It follows Investigational Device Exemption (IDE) approval in the US in August 2022. SELUTION SLR is the first and only limus release drug-eluting balloon (DEB) to receive FDA IDE approval for SFA and PPA indications.

    MedAlliance Enrolls First US Patient into its Third FDA IDE Study: SFA SELUTION4SFA

    SELUTION4SFA is being conducted in over 30 centers in the US plus an additional 10 centers worldwide. The study will enroll 300 patients, with the aim of demonstrating the superiority of SELUTION SLR over balloon angioplasty (POBA). The primary efficacy endpoint is primary patency of the target lesion at 12 months and the primary safety endpoint is freedom from death at 30 days. Enrollment into the study will be complete by the end of 2023.

    “We are excited to introduce the first Sirolimus DEB to US patients, and look forward to a rapid enrollment of this important study,” commented Dr. Jay Mathews, Co-Principal Investigator, Manatee Memorial Hospital, Bradenton, Florida. “We hope to learn how this technology can potentially benefit patients with complex peripheral arterial disease.”

    “We are pleased to be enrolling our third IDE study in US patients, and look forward to the results of these three studies as well as future IDE studies to come,” added Jeffrey B. Jump, Chairman and CEO of MedAlliance.

    SELUTION SLR was awarded CE Mark Approval for the treatment of coronary artery disease in May 2020. MedAlliance was the first drug-eluting balloon company to receive FDA Breakthrough Designation status. Currently, three IDE clinical studies are evaluating SELUTION SLR in the US: in CLTI patients with BTK disease; SFA/PPA; and coronary ISR. In addition, MedAlliance received IDE approval for de novo coronary artery lesions in January 2023. This complements the substantial experience that the company has gained with the SELUTION DeNovo and SUCCESS trials in Europe.

    MedAlliance’s unique DEB technology involves MicroReservoirs which contain a combination of biodegradable polymer intermixed with the anti-restenotic drug sirolimus, applied as a coating on the surface of an angioplasty balloon. These MicroReservoirs provide controlled and sustained release of the drug for up to 90 days. MedAlliance’s proprietary CAT™ (Cell Adherent Technology) enables the MicroReservoirs to be coated onto balloons and efficiently transferred to adhere to the vessel lumen when delivered via expansion of the balloon.

    SELUTION SLR is commercially available in Europe, Asia, the Middle East, and the Americas (outside USA) and most other countries where the CE Mark is recognized. Over 10,000 units have been used for patient treatments in routine clinical practice or as part of coronary clinical trials. Please contact us if your centre is interested in participating in this study.

    About MedAlliance

    MedAlliance is medical technology company which announced a staged acquisition by Cordis in October 2022. It is headquartered in Nyon, Switzerland. MedAlliance specializes in the development of ground-breaking technology and commercialization of advanced drug device combination products for the treatment of coronary and peripheral artery disease. For further information, visit: www.medalliance.com

    Media Contact:
    Richard Kenyon
    rkenyon@medalliance.com
    +44 7831 569940

    Photo: https://mma.prnewswire.com/media/2069598/MedAlliance_SLR_DEB.jpg
    Logo: https://mma.prnewswire.com/media/1196864/MedAlliance_Logo.jpg

    MedAlliance Logo

    Cision View original content:https://www.prnewswire.com/ae/news-releases/medalliance-enrolls-first-us-patient-into-its-third-fda-ide-study-sfa-selution4sfa-301815844.html

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

    Related Posts

    PR Newswire

    Ajman Government Media Office hosts Foreign Affairs Undersecretary at THE SIGNAL with a clear message: ‘The UAE does not seek the signal – it creates it’

    November 22, 2026
    PR Newswire

    Humaid bin Ammar attends day two of Ajman Media Forum 2026 and honours participants and partners

    November 22, 2026
    PR Newswire

    Ajman Government Media Office’s THE SIGNAL forum features Saeed Al Eter on how public trust and a successful development model underpin UAE soft power in times of crisis

    November 22, 2026
    Latest News

    Guinea ends mpox outbreak more than two years after first case

    November 21, 2026

    WFP warns funding gaps will leave millions hungry in 2027

    November 21, 2026

    Chip boom lifts South Korea into $1 trillion export club

    November 21, 2026

    Air Arabia Egypt launches Cairo to Al Ain flights soon

    November 20, 2026

    Botswana reviews proposed 33% power tariff hike today

    November 19, 2026

    PM Modi meets Prince and Princess of Wales for climate talks

    November 19, 2026

    Petrol price jump lifts South Africa inflation as SARB weighs rates

    November 18, 2026

    Ebola adds 60 cases in a day as Congo deaths hit 5,568

    November 18, 2026
    © 2026 Doha Mirror | All Rights Reserved
    • Home
    • Contact Us

    Type above and press Enter to search. Press Esc to cancel.